The FDA recently approved the first eyedrop to treat age-related nearsightness due to poor accommodation, a disorder experienced by more than 100 million Americans. Spoiler alert . . . its pilocarpine eye drops - which have been on the market for over 70 years. What does the data say about this new formulation of an old drug and its ability to help with age-related presbyopia? Listen in for a discussion on efficacy and cost.
Redeem your CPE or CME credit here!
Need a membership?
References and resources:
Continuing Education Information:
0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-22-040-H01-P
Initial release date: 01/10/22
Expiration date: 01/10/2023
Additional CPE & CME details can be found here